Kardigan, Inc.
NASDAQ: KARD0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Tassos Gianakakos
- Employees
- 231
- Headquarters
- Princeton, United States
- IPO year
- 2026
- Market cap
- $2.2B
- Website
- http://www.kardigan.bio
Loading KARD…
Loading profile data…Frequently asked questions about KARD
What does Kardigan, Inc. (KARD) do?
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence...
Where does KARD trade?
Kardigan, Inc. (KARD) trades on the NASDAQ.
What sector is KARD in?
Kardigan, Inc. (KARD) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Kardigan, Inc.?
Tassos Gianakakos is the chief executive officer of Kardigan, Inc. (KARD).
Where is Kardigan, Inc. headquartered?
Kardigan, Inc. is headquartered in United States.
Does KARD pay a dividend?
Kardigan, Inc. (KARD) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KARD go public?
Kardigan, Inc. (KARD) completed its initial public offering in 2026.